oral use
Sponsors
Mirum Pharmaceuticals Inc., Bristol-Myers Squibb Services Unlimited Company, Amylyx Pharmaceuticals Inc., Neuroderm Ltd., Exelixis Inc.
Conditions
Amyotrophic Lateral Sclerosis (ALS)Anxiety in children before surgery.Functional DyspepsiaJuvenile Psoriatic Arthritis (JPsA)Metastatic Medullary Thyroid CancerModerate to Severe Plaque PsoriasisParkinson's diseasePruritus associated with Primary Sclerosing Cholangitis (PSC)
Phase 2
Phase 3
Effect of Zolpidem and Midazolam on anxiety of children
Active, not recruitingIRCT20141127020112N7
Start: 2018-07-27Target: 56Updated: 2019-01-14
A multicenter, randomized, active-controlled, double-blind, double-dummy, parallel group clinical trial, investigating the efficacy, safety, and tolerability of continuous subcutaneous ND0612 infusion in comparison to oral IR-LD/CD in subjects with Parkinson’s disease experiencing motor fluctuations (BouNDless)
Active, not recruitingCTIS2024-511940-20-00
Start: 2020-02-05Target: 156Updated: 2025-11-17
A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial to Evaluate the Safety and Efficacy of AMX0035 Versus Placebo for 48-week Treatment of Adult Patients with Amyotrophic Lateral Sclerosis (ALS)
CompletedCTIS2023-508511-23-00
Start: 2021-12-02End: 2025-01-13Target: 526Updated: 2024-08-04
A Phase 3, Multicenter, Double-blind, Placebo-controlled, Randomized Withdrawal Trial to Evaluate the Efficacy, Safety, and Pharmacokinetics of Deucravacitinib in Children and Adolescents from 5 to less than 18 Years of Age with Active Juvenile Psoriatic Arthritis
RecruitingCTIS2024-517262-41-00
Start: 2025-02-28Target: 29Updated: 2025-12-08
A Multicenter, Randomized, Double-Blind Placebo-Controlled Phase 3 Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Deucravacitinib in Adolescent Subjects (12 years to less than 18 years) with Moderate to Severe Plaque Psoriasis
RecruitingCTIS2023-506296-97-00
Start: 2025-10-28Target: 145Updated: 2025-10-13
Phase 4
Budesonide as a treatment for low-grade duodenal inflammation in functional dyspepsia.
RecruitingCTIS2024-517035-43-00
Start: 2024-05-01Target: 56Updated: 2025-10-31
A Randomized, Double-blind Study to Evaluate the Efficacy and Safety of Cabozantinib (XL184) at 60 mg/Day Compared to 140 mg/Day in Progressive, Metastatic Medullary Thyroid Cancer Patients
Active, not recruitingCTIS2024-516480-90-00
Start: 2015-11-23Target: 10Updated: 2025-12-17